Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - iperkolesterolemija - aġenti li jimmodifikaw il-lipidi - lojuxta huwa indikat bħala frozen dieta low‑fat u lipid‑lowering prodotti mediċinali oħra jew mingħajru baxxa density-lipoprotein (ldl) aferesi fil-pazjenti adulti ma hypercholesterolaemia homozygous familjari (hofh). Ġenetiċi-konferma tal-hofh għandu jinkiseb kull meta jkun possibbli. - forom l-oħra tal-primarja hyperlipoproteinaemia u l-kawżi sekondarji ta ' l-iperkolesterolimja (e. sindromu nefrotiku, ipotirojdiżmu) għandhom jiġu esklużi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

hra pharma rare diseases - mitotane - neoplażmi adrenali tal-kortiċi - aġenti antineoplastiċi - trattament sintomatiku ta 'karċinoma adrenali kortikali avvanzata (mhux ripressibbli, metastatika jew mkasħa). l-effett ta'lysodren fuq karċinoma fil-kortiċi adrenali mhix stabbilita.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

noden pharma dac - aliskiren - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - fibrożi pulmonari idjopatika - aġenti antineoplastiċi - ofev huwa indikat fl-adulti għat-trattament tal-fibrożi pulmonari idjopatika (ipf).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - aġenti antineoplastiċi - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5. topotecan flimkien ma ' cisplatin huwa indikat għall-pazjenti b'karċinoma taċ-ċerviċi rikorrenti wara radjuterapija u għall-pazjenti bil-marda fl-istadju ivb. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - aġenti antineoplastiċi - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - pazopanib - karċinoma, Ċellula renali - aġenti antineoplastiċi - tal-kliewi-karċinoma taċ-ċellola (rcc)votrient huwa indikat fl-adulti għall-ewwel linja ta ' trattament ta avvanzat tal-kliewi-karċinoma taċ-ċellola (rcc) u għall-pazjenti li rċevew terapija minn qabel b'ċitokini għal marda avvanzata. sarkoma tat-tessuti rotob (sts)votrient huwa indikat għall-kura ta 'pazjenti adulti b'selettiv sottotipi ta' sarkoma tat-tessuti rotob (sts) u li jkunu ħadu l-kimoterapija qabel, għal mard metastatiku jew li għamlu progress fi żmien 12-il xahar ta'wara (neo)terapija miżjuda. l-effikaċja u s-sigurtà għandhom biss ġewx stabbiliti f'ċerti sts istoloġika tat-tumur sottotipi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - lewkimja, linfokitika, kronika, b-Ċellula - aġenti antineoplastiċi - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - pixantrone dimaleate - limfoma, mhux hodgkin - aġenti antineoplastiċi - pixuvri huwa indikat bħala monoterapija għat-trattament ta 'pazjenti adulti li għandhom limfomi ċellulari b mhux multipli li jirkadu jew refrattarji aggressivi (nhl). il-benefiċċju tat-trattament ta 'pixantrone ma ġiex stabbilit f'pazjenti meta jintuża bħala kimoterapija tal-ħames linja jew ikbar f'pazjenti li huma refrattorji għall-aħħar terapija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - vargatef hija indikata fil kombinazzjoni ma jeanne għat-trattament tal-pazjenti adulti b ' kanċer tal-pulmun avvanzat lokalment, metastatic jew rikorrenti lokalment taċ-ċellola mhux-żgħira (nsclc) ta ' adenocarcinoma tumur istoloġija wara l-ewwel linja chemotherapy.